Searched for: in-biosketch:true
person:velchv01
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
Huang, Min; Lou, Yanyan; Pellissier, James; Burke, Thomas; Liu, Frank Xiaoqing; Xu, Ruifeng; Velcheti, Vamsidhar
OBJECTIVES/OBJECTIVE:This analysis aimed to evaluate the cost-effectiveness of pembrolizumab compared with docetaxel in patients with previously treated advanced non-squamous cell lung cancer (NSCLC) with PD-L1 positive tumors (total proportion score [TPS] ≥ 50%). The analysis was conducted from a US third-party payer perspective. METHODS:with extrapolation based on fitted parametric functions and long-term registry data. Quality-adjusted life years (QALYs) were derived based on EQ-5D data from KEYNOTE 010 using a time to death approach. Costs of drug acquisition/administration, adverse event management, and clinical management of advanced NSCLC were included in the model. The base-case analysis used a time horizon of 20 years. Costs and health outcomes were discounted at a rate of 3% per year. A series of one-way and probabilistic sensitivity analyses were performed to test the robustness of the results. RESULTS:Base case results project for PD-L1 positive (TPS ≥50%) patients treated with pembrolizumab a mean survival of 2.25 years. For docetaxel, a mean survival time of 1.07 years was estimated. Expected QALYs were 1.71 and 0.76 for pembrolizumab and docetaxel, respectively. The incremental cost per QALY gained with pembrolizumab vs docetaxel is $168,619/QALY, which is cost-effective in the US using a threshold of 3-times GDP per capita. Sensitivity analyses showed the results to be robust over plausible values of the majority of inputs. Results were most sensitive to extrapolation of overall survival. CONCLUSIONS:Pembrolizumab improves survival, increases QALYs, and can be considered as a cost-effective option compared to docetaxel in PD-L1 positive (TPS ≥50%) pre-treated advanced NSCLC patients in the US.
PMID: 27571538
ISSN: 1941-837x
CID: 3237602
Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
Schalper, Kurt A; Carvajal-Hausdorf, Daniel; McLaughlin, Joseph; Altan, Mehmet; Velcheti, Vamsidhar; Gaule, Patricia; Sanmamed, Miguel F; Chen, Lieping; Herbst, Roy S; Rimm, David L
PURPOSE/OBJECTIVE:To determine the expression level, associations, and biological role of PD-L1, IDO-1, and B7-H4 in non-small cell lung cancer (NSCLC). EXPERIMENTAL DESIGN/METHODS:Using multiplexed quantitative immunofluorescence (QIF), we measured the levels of PD-L1, IDO-1, B7-H4, and different tumor-infiltrating lymphoycte (TIL) subsets in 552 stages I-IV lung carcinomas from two independent populations. Associations between the marker levels, TILs, and major clinicopathologic variables were determined. Validation of findings was performed using mRNA expression data from The Cancer Genome Atlas (TCGA) and in vitro stimulation of lung adenocarcinoma A549 cells with IFNγ and IL10. RESULTS:PD-L1 was detected in 16.9% and 21.8% of cases in each population. IDO-1 was expressed in 42.6% and 49.8%; and B7-H4 in 12.8% and 22.6% of cases, respectively. Elevated PD-L1 and IDO-1 were consistently associated with prominent B- and T-cell infiltrates, but B7-H4 was not. Coexpression of the three protein markers was infrequent, and comparable results were seen in the lung cancer TCGA dataset. Levels of PD-L1 and IDO-1 (but not B7-H4) were increased by IFNγ stimulation in A549 cells. Treatment with IL10 upregulated B7-H4 but did not affect PD-L1 and IDO-1 levels. CONCLUSIONS:PD-L1, IDO-1, and B7-H4 are differentially expressed in human lung carcinomas and show limited co-expression. While PD-L1 and IDO-1 are associated with increased TILs and IFNγ stimulation, B7-H4 is not. The preferential expression of discrete immune evasion pathways in lung cancer could participate in therapeutic resistance and support design of optimal clinical trials. Clin Cancer Res; 23(2); 370-8. ©2016 AACR.
PMID: 27440266
ISSN: 1078-0432
CID: 3237582
A lymphocyte spatial distribution graph based method for automated classification of recurrence risk on lung cancer images
Chapter by: Garcia-Arteaga, Juan D.; Corredor, German; Wang, Xiangxue; Velcheti, Vamsidhar; Madabhushi, Anant; Romero, Eduardo
in: 13TH INTERNATIONAL CONFERENCE ON MEDICAL INFORMATION PROCESSING AND ANALYSIS by ; Romero, E; Lepore, N; Brieva, J; Garcia, JD
BELLINGHAM : SPIE-INT SOC OPTICAL ENGINEERING, 2017
pp. ?-?
ISBN: 978-1-5106-1634-9
CID: 3238072
Quantifying Expert Diagnosis Variability when grading Tumor-Infiltrating Lymphocytes
Chapter by: Toro, Paula; Corredor, German; Wang, Xiangxue; Arias, Viviana; Velcheti, Vamsidhar; Madabhushi, Anant; Romero, Eduardo
in: 13TH INTERNATIONAL CONFERENCE ON MEDICAL INFORMATION PROCESSING AND ANALYSIS by ; Romero, E; Lepore, N; Brieva, J; Garcia, JD
BELLINGHAM : SPIE-INT SOC OPTICAL ENGINEERING, 2017
pp. ?-?
ISBN: 978-1-5106-1634-9
CID: 3238062
Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases [Editorial]
Calabrese, Leonard; Velcheti, Vamsidhar
PMID: 27566797
ISSN: 1468-2060
CID: 3237592
Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer
Velcheti, Vamsidhar; Radivoyevitch, Tomas; Saunthararajah, Yogen
Searches for effective yet nontoxic oncotherapies are searches for exploitable differences between cancer and normal cells. In its core of cell division, cancer resembles normal life, coordinated by the master transcription factor MYC. Outside of this core, apoptosis and differentiation programs, which dominantly antagonize MYC to terminate cell division, necessarily differ between cancer and normal cells, as apoptosis is suppressed by biallelic inactivation of the master regulator of apoptosis, p53, or its cofactor p16/CDKN2A in approximately 80% of cancers. These genetic alterations impact therapy: conventional oncotherapy applies stress upstream of p53 to upregulate it and causes apoptosis (cytotoxicity)-a toxic, futile intent when it is absent or nonfunctional. Differentiation, on the other hand, cannot be completely suppressed because it is a continuum along which all cells exist. Neoplastic evolution stalls advances along this continuum at its most proliferative points-in lineage-committed progenitors that have division times measured in hours compared with weeks for tissue stem cells. This differentiation arrest is by mutations/deletions in differentiation-driving transcription factors or their coactivators that shift balances of gene-regulating protein complexes toward corepressors that repress instead of activate hundreds of terminal differentiation genes. That is, malignant proliferation without differentiation, also referred to as cancer "stem" cell self-renewal, hinges on druggable corepressors. Inhibiting these corepressors (e.g., DNMT1) releases p53-independent terminal differentiation in cancer stem cells but preserves self-renewal of normal stem cells that express stem cell transcription factors. Thus, epigenetic-differentiation therapies exploit a fundamental distinction between cancer and normal stem cell self-renewal and have a pathway of action downstream of genetic defects in cancer, affording favorable therapeutic indices needed for clinical progress.
PMID: 28561650
ISSN: 1548-8756
CID: 3237712
PS01.54: Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-F1RST): Topic: Medical Oncology
Socinski, Mark A; Schiller, Joan; Dakhil, Shaker; Kazmi, Shayma; Leach, Joseph; Hu, Sylvia; Paul, Sarah M; Shames, David S; Phan, See; Yun, Cindy; Velcheti, Vamsidhar
PMID: 27969521
ISSN: 1556-1380
CID: 3237642
Breast Mass in a Woman with Recurrent Thymoma [Letter]
Sturgis, Charles D; Ataya, Dana; Calhoun, Benjamin C; Velcheti, Vamsidhar; Mukhopadhyay, Sanjay
PMID: 27831813
ISSN: 2325-6621
CID: 3237622
Adjuvant Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Yes, No, Maybe So? [Comment]
Davis, Mellar P; Velcheti, Vamsidhar; Pennell, Nathan A
PMID: 27287563
ISSN: 1931-3543
CID: 3237572
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma
Vassilakopoulou, Maria; Avgeris, Margaritis; Velcheti, Vamsidhar; Kotoula, Vassiliki; Rampias, Theodore; Chatzopoulos, Kyriakos; Perisanidis, Christos; Kontos, Christos K; Giotakis, Aris I; Scorilas, Andreas; Rimm, David; Sasaki, Clarence; Fountzilas, George; Psyrri, Amanda
PURPOSE/OBJECTIVE:Programmed death-ligand 1 (PD-L1; also known as CD274 or B7-H1) expression represents a mechanism of immune escape for cancer. Our purpose was to characterize tumor PD-L1 expression and associated T-cell infiltration in primary laryngeal squamous cell carcinomas (SCC). EXPERIMENTAL DESIGN/METHODS:A well-annotated cohort of 260 operable primary laryngeal SCCs [formalin-fixed paraffin-embedded (FFPE) specimens] was morphologically characterized for stromal tumor-infiltrating lymphocytes (TIL), on hematoxylin/eosin-stained whole sections and for PD-L1 mRNA expression by qRT-PCR in FFPE specimens. For PD-L1 protein expression, automated quantitative protein analysis (AQUA) was applied on tissue microarrays consisting of two cores from these tumors. In addition, PD-L1 mRNA expression in fresh-frozen tumors and normal adjacent tissue specimens was assessed in a second independent cohort of 89 patients with primary laryngeal SCC. RESULTS:PD-L1 mRNA levels were upregulated in tumors compared with surrounding normal tissue (P = 0.009). TILs density correlated with tumor PD-L1 AQUA levels (P = 0.021). Both high TILs density and high PD-L1 AQUA levels were significantly associated with superior disease-free survival (DFS; TILs: P = 0.009 and PD-L1: P = 0.044) and overall survival (OS; TILs: P = 0.015 and PD-L1: P = 0.059) of the patients and retained significance in multivariate analysis. CONCLUSIONS:Increased TILs density and PD-L1 levels are associated with better outcome in laryngeal squamous cell cancer. Assessment of TILs and PD-L1 expression could be useful to predict response to immune checkpoint inhibitors.
PMID: 26408403
ISSN: 1078-0432
CID: 3237522